Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Rapid Response Innovation Awards, 2011
    Alpha-Synuclein Knockdown: Therapeutic or Toxic?

    Objective/Rationale:
    The protein alpha-synuclein (a-syn) has been conclusively linked to Parkinson’s disease. The prevailing theory today states that a-syn is a causative agent in the development of...

  • Improving Levodopa Delivery, 2011
    Dry Powder-Based Delivery of Intrapulmonary Levodopa as a Treatment for Motor Fluctuations in Parkinson's Disease

    Objective/Rationale:
    Oral levodopa pharmacokinetics are subject to excessive within- and between-subject variability, reflecting challenges inherent to gastrointestinal delivery. Aerosol delivery of...

  • LRRK2, 2011
    LRRK2 Physiology in Parkinson's Disease

    Objective/Rationale:
    Mutations in the LRRK2 gene are a common cause of genetic Parkinson’s disease. LRRK2 is highly expressed in circulating and tissue immune cells. We have recently identified that...

  • Target Validation, 2011
    Pathway Validation of a Biased Delta Opioid Receptor Ligand for PD Symptoms & Side Effects Relief

    Objective/Rationale:
    Endogenous activation of the Delta opioid receptor (DOR) serves as a compensatory mechanism to alleviate Parkinson’s disease (PD) symptoms. However, DOR-mediated convulsions have...

  • Dyskinesia, 2011
    Targeting Dramatically Activated Astrocytic Networks for Managing LID: a Target Validation Program

    Objective/Rationale:
    Astrocytes have long been regarded as passive partners of neurons in the central nervous system but this view has been challenged. Although astrocytes are now known to actively...

  • Research Grant, 2011
    Identifying Markers of PD Onset and Progression in a Prospective Cohort of Patients and ASymptoms & Side Effects Carriers of LRRK2 Mutations

    Objective/Rationale:
    LRRK2 mutations constitute one of the most common genetic risk factors for PD. The prospective follow-up of PD patients and aSymptoms & Side Effects carriers of LRRK2 mutations...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.